A new method using gas chromatography/mass spectrometry was developed to screen and quantify seven 2C-series designer drugs (2C-D, 2C-E, 2C-P, 2C-B, 2C-I, 2C-T-2, 2C-T-7) and mescaline in human blood plasma. The method involves solid-phase extraction and derivatization, and was validated per international guidelines. Validation for 2C-T-2 and 2C-T-7 was unacceptable; for the other analytes, the method was linear from 5 to 500 microg/L with accuracy and precision within acceptable limits. This addresses the scarcity of data on analyzing these substances in blood or plasma.
Cytochrome P450 isozymes responsible for metabolizing the designer drug MBDB (Eden) were identified for the first time. The main metabolites produced are DHMBB and BDB. Dealkylation is primarily catalyzed by CYP2B6 and CYP2C19, while demethylenation also involves CYP1A2, CYP2D6, and CYP3A4. After in vitro-in vivo correlation, CYP2D6 is the most abundant isozyme for total MBDB metabolism, and CYP2C19 is the most enantioselective, metabolizing the S-enantiomer at a higher rate at low substrate concentrations. Inhibition studies with quinidine confirmed CYP2D6's dominant role. These findings align with results for similar amphetamines.